ENZN: Enzon Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ENZN: Enzon Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 11.13
Enterprise Value ($M) 8.58
Book Value ($M) 46.84
Book Value / Share 0.63
Price / Book 0.24
NCAV ($M) 46.53
NCAV / Share 0.63
Price / NCAV 0.24

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.03
Return on Equity (ROE) 0.03

Liquidity (mrq)
Quick Ratio 107.24
Current Ratio 107.24

Balance Sheet (mrq) ($M)
Current Assets 46.97
Assets 47.28
Liabilities 0.44
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
12-19 13D/A Icahn Carl C

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-03-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)

Similar Companies
ELTP – Elite Pharmaceuticals, Inc. ELVAF – Evolva Holding SA
EMMA – Emmaus Life Sciences, Inc. ERGO – Entia Biosciences, Inc.
ETNI – Entest Group, Inc.


Financial data and stock pages provided by
Fintel.io